Biogen report positive Results From Phase 3 Study of biosimilar tocilizumab in rheumatoid arthritis

In the study, this biosimilar met the primary endpoint, demonstrating clinical equivalence (ACR20 response) vs the reference product RoActermra in patients with moderate to severe rheumatoid arthritis inadequately controlled by methotrexate therapy.

Source:

Biospace Inc.